A Double-Blind, Randomized, Placebo-Controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2012

At a glance

  • Drugs Enzastaurin (Primary)
  • Indications Brain metastases; Lung cancer
  • Focus Therapeutic Use
  • Acronyms MENZA
  • Most Recent Events

    • 02 Oct 2012 Primary endpoint 'Time-to-disease-progression' has not been met.
    • 01 Oct 2012 Final results published in Lung Cancer.
    • 20 Jan 2011 Actual end date (January 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top